"Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.


Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
07 07 2020
Historique:
pubmed: 18 2 2020
medline: 10 4 2021
entrez: 18 2 2020
Statut: ppublish

Résumé

AbstractThe T2-FLAIR (fluid attenuated inversion recovery) mismatch sign is an easily detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate dehydrogenase (IDH)-mutant 1p/19q non-codeleted gliomas. Multiple independent studies show that the T2-FLAIR mismatch sign has near-perfect specificity, but low sensitivity for diagnosing IDH-mutant astrocytomas. Thus, the T2-FLAIR mismatch sign represents a non-invasive radiogenomic diagnostic finding with potential clinical impact. Recently, false positive cases have been reported, many related to variable application of the sign's imaging criteria and differences in image acquisition, as well as to differences in the included patient populations. Here we summarize the imaging criteria for the T2-FLAIR mismatch sign, review similarities and differences between the multiple validation studies, outline strategies to optimize its clinical use, and discuss potential opportunities to refine imaging criteria in order to maximize its impact in glioma diagnostics.

Identifiants

pubmed: 32064507
pii: 5737809
doi: 10.1093/neuonc/noaa041
pmc: PMC7339896
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

936-943

Subventions

Organisme : NCI NIH HHS
ID : P50 CA165962
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

AJNR Am J Neuroradiol. 2013 Mar;34(3):533-40
pubmed: 22997168
Clin Cancer Res. 2017 Oct 15;23(20):6078-6085
pubmed: 28751449
Metabolites. 2017 Jun 19;7(2):
pubmed: 28629182
J Comput Assist Tomogr. 2007 May-Jun;31(3):348-53
pubmed: 17538277
Neurology. 2004 Dec 28;63(12):2360-2
pubmed: 15623700
AJNR Am J Neuroradiol. 2018 Apr;39(4):687-692
pubmed: 29519793
J Magn Reson Imaging. 2005 Jul;22(1):13-22
pubmed: 15971174
Brain. 2006 Jul;129(Pt 7):1884-91
pubmed: 16670176
Nat Med. 2012 Jan 26;18(4):624-9
pubmed: 22281806
AJNR Am J Neuroradiol. 2018 Jan;39(1):37-42
pubmed: 29122763
AJNR Am J Neuroradiol. 2017 Mar;38(3):492-499
pubmed: 28034994
Eur Radiol. 2020 Feb;30(2):844-854
pubmed: 31446467
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuroradiology. 2011 Jun;53(6):405-11
pubmed: 20644924
Neuro Oncol. 2018 Jan 10;20(1):103-112
pubmed: 29016833
J Neurooncol. 2019 Jan;141(2):327-335
pubmed: 30536195
Radiology. 2008 Oct;249(1):268-77
pubmed: 18796682
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):224-7
pubmed: 20587495
J Neurooncol. 2016 Sep;129(3):505-514
pubmed: 27401154
Sci Transl Med. 2012 Jan 11;4(116):116ra4
pubmed: 22238332
AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55
pubmed: 22322613
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Clin Cancer Res. 2004 Jul 1;10(13):4303-6
pubmed: 15240515
Ann Oncol. 2017 Aug 1;28(8):1942-1948
pubmed: 28475680
Brain Tumor Pathol. 2016 Jul;33(3):175-82
pubmed: 26849373
AJNR Am J Neuroradiol. 2019 Mar;40(3):426-432
pubmed: 30705071
Acta Neuropathol. 2018 Jul;136(1):153-166
pubmed: 29687258
Eur J Cancer. 2019 Jan;107:15-27
pubmed: 30529899
Neuro Oncol. 2018 Sep 3;20(10):1393-1399
pubmed: 29590424
Neuro Oncol. 2014 Jan;16(1):81-91
pubmed: 24305719
Am J Clin Pathol. 1995 Jun;103(6):705-9
pubmed: 7785654
AJNR Am J Neuroradiol. 2017 Apr;38(4):678-684
pubmed: 28126746
J Neurosurg. 2013 Aug;119(2):434-41
pubmed: 23662821
Eur Neurol. 2018;79(5-6):317-318
pubmed: 29986339
Neuroradiology. 2019 Feb;61(2):225-227
pubmed: 30565056

Auteurs

Rajan Jain (R)

Departments of Radiology and Neurosurgery, New York University Langone Health, New York, New York, USA.

Derek R Johnson (DR)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Sohil H Patel (SH)

Department of Radiology, University of Virginia Health, Charlottesville, Virginia, USA.

Mauricio Castillo (M)

Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA.

Marion Smits (M)

Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands.

Martin J van den Bent (MJ)

Department of Neurology, Erasmus MC, Rotterdam, Netherlands.

Andrew S Chi (AS)

Mirati Therapeutics, San Diego, California, USA.

Daniel P Cahill (DP)

Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH